Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study
Loading...
Date
Authors
Saougou, I.
Markatseli, T. E.
Papagoras, C.
Voulgari, P. V.
Alamanos, Y.
Drosos, A. A.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Semin Arthritis Rheum
Book name
Book series
Book edition
Alternative title / Subtitle
Description
OBJECTIVE: To investigate the efficacy, toxicity, and drug discontinuation in patients with psoriatic arthritis treated with anti-tumor necrosis factor agents. METHODS: Sixty-five patients with active disease were included in this open-label study. They had tender or swollen joint count >/=5, Psoriatic Arthritis Severity Index (PASI) score >/=10, and erythrocyte sedimentation rate >/=28 mm Hg/1st hour and/or C-reactive protein >/=10 mg/L. All were refractory to at least 2 disease-modifying antirheumatic drugs. Thirty were treated with infliximab, 25 with etanercept, and 10 with adalimumab. Infliximab (5 mg/kg body weight) was given intravenously at weeks 0, 2, 6, and every 8 weeks thereafter; etanercept was given subcutaneously (25 mg twice a week), while adalimumab was given subcutaneously (40 mg every other week) for a period of 5 years. Data concerning anti-tumor necrosis factor efficacy tolerability, adverse events, and drug discontinuation were recorded. The percentage of patients who achieved the Psoriatic Arthritis Response Criteria (PSARC), the improvement of PASI, the improvement according to the American College of Rheumatology (ACR) criteria, and the disease activity for 28 joint indices score (DAS-28) were recorded. RESULTS: After 5 years, PSARC was 60%, PASI 70 was 66.7%, PASI 90 was 63.3%, while ACR 50 was 56.7% for the patients treated with infliximab. Moreover, PsARC was 64%, PASI 70 and PASI 90 were 68%, while ACR 50 was 56% for those treated with etanercept. Furthermore, in the adalimumab group PsARC was 56%, PASI 70 and PASI 90 were 58% and 50%, respectively, while ACR 50 was 50%. Additionally, DAS-28 scores were significantly improved. Thirteen patients treated with infliximab, 6 with etanercept, and 5 patients with adalimumab were withdrawn. At the end of treatment, the survival of infliximab was 56.7%, for etanercept 76%, and for adalimumab 50%. CONCLUSION: All drugs were effective, safe, and well-tolerated. The clinical improvement was maintained through the 5 years with satisfying infliximab and adalimumab survival and high etanercept survival.
Description
Keywords
Adult, Antibodies, Monoclonal/*therapeutic use, Antibodies, Monoclonal, Humanized, Arthritis, Psoriatic/blood/*drug therapy/mortality, Blood Sedimentation, C-Reactive Protein/metabolism, Cohort Studies, Female, Humans, Immunoglobulin G/*therapeutic use, Longitudinal Studies, Male, Middle Aged, Receptors, Tumor Necrosis Factor/*therapeutic use, Retrospective Studies, Survival Rate, Treatment Outcome, Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/20843542
http://ac.els-cdn.com/S0049017210001435/1-s2.0-S0049017210001435-main.pdf?_tid=cda819ec128a7dfeac9c7d88ffa57fc4&acdnat=1333526545_759b788ae22afd2865dbd0f8fff4f3f7
http://ac.els-cdn.com/S0049017210001435/1-s2.0-S0049017210001435-main.pdf?_tid=cda819ec128a7dfeac9c7d88ffa57fc4&acdnat=1333526545_759b788ae22afd2865dbd0f8fff4f3f7
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής